Candidate Compounds Covid19

(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
Zeile 30: Zeile 30:
 
*[[TGF beta]]
 
*[[TGF beta]]
 
*[[Immunosuppressants]]  
 
*[[Immunosuppressants]]  
−
*[[Interferons]]
 
 
*[[Anticoagulant in covid19]]
 
*[[Anticoagulant in covid19]]
−
 
+
*[[Antioxidants]]
−
 
+
*[[HIF-EPO-Iron]]
 
*[[Stem cells]]
 
*[[Stem cells]]
 
*[[MDSC cells]]
 
*[[MDSC cells]]
−
 
+
*[[Interferons]]
−
*[[Antibiotics]]
+
 
*[[cAMP cGMP PDE NO]]
 
*[[cAMP cGMP PDE NO]]
 
*[[TRPV* channels]]
 
*[[TRPV* channels]]
 
*[[Retinoids]]
 
*[[Retinoids]]
 +
*[[Protease inhibitors]]
 
*[[Tyrosine kinase inhibitors]]
 
*[[Tyrosine kinase inhibitors]]
 
*[[Antineoplastic agents, traditional]]
 
*[[Antineoplastic agents, traditional]]
 
*[[Mouthrinses]]
 
*[[Mouthrinses]]
 +
*[[Adenosinergic signaling]]
 
*[[Purinergic signaling]]
 
*[[Purinergic signaling]]
 
*[[Nicotinergic signaling]]
 
*[[Nicotinergic signaling]]
−
 
−
*[[Statins]]
 
−
*[[Antidiabetic compounds, any]]
 
−
*[[RSP - On RAS drugs]]
 
  
  
Zeile 65: Zeile 61:
 
*[[AV Favipiravir]]
 
*[[AV Favipiravir]]
  
−
*[[HIF-EPO-Iron]]
+
*[[Antibiotics]]
−
*[[Antioxidants]]
+
 
 +
 
 
*[[Vitamin D]]
 
*[[Vitamin D]]
 
*[[Anorganic nutrients Magnesium]]
 
*[[Anorganic nutrients Magnesium]]
Zeile 80: Zeile 77:
 
*[[Traditional Chinese Medicine]]
 
*[[Traditional Chinese Medicine]]
 
*[[Natural compounds]]
 
*[[Natural compounds]]
 +
 +
*[[Statins]]
 +
*[[Antidiabetic compounds, any]]
 +
*[[RSP - On RAS drugs]]
 +
*[[RSP - On NSAIDs]]
  
 
*[[Reconvalescent blood products, Passive vaccine]]  
 
*[[Reconvalescent blood products, Passive vaccine]]  
Zeile 91: Zeile 93:
 
*[[Treatment other concepts]]
 
*[[Treatment other concepts]]
  
−
===-rest-===
 
  
  
Zeile 101: Zeile 102:
  
  
 +
{{tp|p=32445955|t=2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"|pdf=|usr=009}}
  
  
Zeile 119: Zeile 121:
  
  
 +
{{tp|p=32426002|t=2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.|pdf=|usr=009}}
  
  
Zeile 135: Zeile 138:
  
  
 +
{{tp|p=32376108|t=2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.|pdf=|usr=009}}
  
  
Zeile 140: Zeile 144:
  
  
−
===009===
 
  
 +
{{tp|p=32426090|t=2020. COVID-19, asthma, and biologic therapies: What we need to know.|pdf=|usr=009}}
  
 +
{{tp|p=32514854|t=2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.|pdf=|usr=009}}
  
  
Zeile 153: Zeile 158:
  
  
−
{{tp|p=32459647|t=2020. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.|pdf=|usr=009}}
 
  
  
Zeile 169: Zeile 173:
  
  
 +
{{tp|p=32558354|t=2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.|pdf=|usr=010}}
  
  
  
  
 +
{{tp|p=32562159|t=2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.|pdf=|usr=010}}
  
  
Zeile 181: Zeile 187:
  
  
 +
{{tp|p=32592145|t=2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.|pdf=|usr=010}}
  
  
  
  
−
{{tp|p=32464494|t=2020. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.|pdf=|usr=009}}
+
{{tp|p=32562594|t=2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.|pdf=|usr=010}}
  
  
−
{{tp|p=32464492|t=2020. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?|pdf=|usr=009}}
+
{{tp|p=32578073|t=2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.|pdf=|usr=010}}
 +
{{tp|p=32577840|t=2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.|pdf=|usr=010}}
  
  
 +
{{tp|p=32588335|t=2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.|pdf=|usr=010}}
  
  
Zeile 196: Zeile 205:
  
  
−
{{ttp|p=32516733|t=2020. B-cell engineering: A promising approach towards vaccine development for COVID-19.|pdf=|usr=009}}
 
  
  
−
{{tp|p=32505075|t=2020. Fighting against frailty and sarcopenia - As well as COVID-19?|pdf=|usr=009}}
 
  
−
{{tp|p=32505069|t=2020. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.|pdf=|usr=009}}
 
  
  
Zeile 207: Zeile 213:
  
  
−
{{tp|p=32473390|t=2020. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?|pdf=|usr=009}}
 
  
 +
{{tp|p=32552021|t=2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.|pdf=|usr=010}}
  
−
{{tp|p=32442649|t=2020. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.|pdf=|usr=009}}
 
  
 +
{{tp|p=32551560|t=2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.|pdf=|usr=010}}
  
  
−
{{tp|p=32445439|t=2020. Surgery Scheduling in a Crisis.|pdf=|usr=009}}
+
{{tp|p=32561608|t=2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.|pdf=|usr=010}}
 +
{{tp|p=32574109|t=2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.|pdf=|usr=010}}
  
  
Zeile 223: Zeile 230:
  
  
−
{{tp|p=32431755|t=2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.|pdf=|usr=009}}
 
−
{{tp|p=32451736|t=2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.|pdf=|usr=009}}
 
  
−
{{tp|p=32445955|t=2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"|pdf=|usr=009}}
 
  
−
{{tp|p=32430287|t=2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.|pdf=|usr=009}}
+
{{tp|p=32567239|t=2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.|pdf=|usr=010}}
  
  
−
{{tp|p=32405226|t=2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.|pdf=|usr=009}}
 
  
  
  
  
−
{{tp|p=32470470|t=2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.|pdf=|usr=009}}
 
−
{{tp|p=32442437|t=2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.|pdf=|usr=009}}
 
−
{{tp|p=32437972|t=2020. COVID-19: Beyond the virus. The use of Photodynamic Therapy for the Treatment of Infections in the Respiratory Tract.|pdf=|usr=009}}
 
  
−
{{tp|p=32493609|t=2020. SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?|pdf=|usr=009}}
 
  
−
{{tp|p=32415971|t=2020. Use of statins in patients with COVID-19.|pdf=|usr=009}}
 
−
{{tp|p=32415962|t=2020. Reply: Use of statins in patients with COVID-19.|pdf=|usr=009}}
 
−
{{tp|p=32522574|t=2020. Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?|pdf=|usr=009}}
 
  
  
−
{{tp|p=32426002|t=2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.|pdf=|usr=009}}
 
  
  
−
{{tp|p=32414660|t=2020. Exercising in times of COVID-19: what do experts recommend doing within four walls?|pdf=|usr=009}}
 
  
  
Zeile 257: Zeile 251:
  
  
−
{{tp|p=32412544|t=2020. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme.|pdf=|usr=009}}
 
  
  
−
{{tp|p=32436460|t=2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.|pdf=|usr=009}}
 
  
−
{{tp|p=32406985|t=2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.|pdf=|usr=009}}
 
  
−
{{tp|p=32376108|t=2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.|pdf=|usr=009}}
 
  
  
  
  
−
{{tp|p=32532094|t=2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.|pdf=|usr=009}}
 
  
−
{{tp|p=32426090|t=2020. COVID-19, asthma, and biologic therapies: What we need to know.|pdf=|usr=009}}
 
  
−
{{tp|p=32514854|t=2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.|pdf=|usr=009}}
 
  
  
Zeile 282: Zeile 269:
  
  
−
{{tp|p=32574894|t=2020. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.|pdf=|usr=010}}
+
{{tp|p=32587103|t=2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?|pdf=|usr=010}}
−
{{tp|p=32583087|t=2020. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.|pdf=|usr=010}}
+
  
  
  
−
{{tp|p=32575554|t=2020. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.|pdf=|usr=010}}
 
  
−
{{tp|p=32557214|t=2020. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.|pdf=|usr=010}}
 
  
  
 +
{{tp|p=32565309|t=2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.|pdf=|usr=010}}
  
−
{{tp|p=32541865|t=2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.|pdf=|usr=010}}
 
  
−
{{tp|p=32585295|t=2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.|pdf=|usr=010}}
 
  
  
  
−
{{tp|p=32558354|t=2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.|pdf=|usr=010}}
 
−
{{tp|p=32552848|t=2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.|pdf=|usr=010}}
 
  
  
−
{{tp|p=32578027|t=2020. A Rapid Advice Guideline for the Prevention of Novel Coronavirus Through Nutritional Intervention.|pdf=|usr=010}}
 
−
{{tp|p=32562159|t=2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.|pdf=|usr=010}}
 
  
  
−
{{tp|p=32537890|t=2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.|pdf=|usr=010}}
 
−
{{tp|p=32592841|t=2020. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.|pdf=|usr=010}}
 
−
{{tp|p=32581194|t=2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?|pdf=|usr=010}}
 
  
 +
{{tp|p=32557955|t=2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.|pdf=|usr=010}}
  
−
{{tp|p=32569833|t=2020. Exportin 1 inhibition as antiviral therapy.|pdf=|usr=010}}
+
{{ttp|p=32579012|t=2020. COVID-19. Immunothrombosis and the gastrointestinal tract.|pdf=|usr=010}}
  
  
−
{{tp|p=32592145|t=2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.|pdf=|usr=010}}
 
−
{{tp|p=32574958|t=2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.|pdf=|usr=010}}
 
  
 +
{{tp|p=32593196|t=2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.|pdf=|usr=010}}
  
  
−
{{tp|p=32562594|t=2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.|pdf=|usr=010}}
 
−
{{tp|p=32561291|t=2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?|pdf=|usr=010}}
 
−
{{tp|p=32554535|t=2020. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors (nAChR) and beyond.|pdf=|usr=010}}
 
−
{{tp|p=32578073|t=2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.|pdf=|usr=010}}
 
−
{{tp|p=32577840|t=2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.|pdf=|usr=010}}
 
−
{{tp|p=32546029|t=2020. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.|pdf=|usr=010}}
 
  
−
{{tp|p=32588335|t=2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.|pdf=|usr=010}}
 
−
{{tp|p=32557206|t=2020. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.|pdf=|usr=010}}
 
  
 +
{{tp|p=32583729|t=2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.|pdf=|usr=010}}
  
  
  
  
−
{{tp|p=32579907|t=2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.|pdf=|usr=010}}
 
  
−
{{tp|p=32592113|t=2020. Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.|pdf=|usr=010}}
 
  
  
Zeile 342: Zeile 309:
  
  
−
{{tp|p=32552021|t=2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.|pdf=|usr=010}}
 
−
{{tp|p=32579022|t=2020. Lung Mechanics in COVID-19 Resemble RDS not ARDS: Could Surfactant be a Treatment?|pdf=|usr=010}}
 
−
{{tp|p=32579020|t=2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?|pdf=|usr=010}}
 
−
{{tp|p=32551560|t=2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.|pdf=|usr=010}}
 
  
 +
{{tp|p=32568012|t=2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.|pdf=|usr=010}}
  
−
{{tp|p=32561608|t=2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.|pdf=|usr=010}}
 
−
{{tp|p=32574109|t=2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.|pdf=|usr=010}}
 
  
  
Zeile 355: Zeile 317:
  
  
−
{{tp|p=32562762|t=2020. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?|pdf=|usr=010}}
 
  
  
−
{{tp|p=32559771|t=2020. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.|pdf=|usr=010}}
 
  
−
{{tp|p=32567239|t=2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.|pdf=|usr=010}}
 
  
  
−
{{tp|p=32552044|t=2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.|pdf=|usr=010}}
 
−
{{tp|p=32576053|t=2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.|pdf=|usr=010}}
 
−
{{tp|p=32553760|t=2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.|pdf=|usr=010}}
 
−
{{tp|p=32553757|t=2020. Aminosalicylates and COVID-19: Facts or Coincidences?|pdf=|usr=010}}
 
−
{{tp|p=32554621|t=2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.|pdf=|usr=010}}
 
  
  
−
{{tp|p=32557541|t=2020. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.|pdf=|usr=010}}
 
−
{{tp|p=32561274|t=2020. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.|pdf=|usr=010}}
 
  
  
  
−
{{tp|p=32562701|t=2020. Apelin-potential therapy for COVID-19?|pdf=|usr=010}}
 
  
  
Zeile 381: Zeile 332:
  
  
−
{{tp|p=32555296|t=2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).|pdf=|usr=010}}
 
  
  
−
{{tp|p=32590324|t=2020. Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.|pdf=|usr=010}}
 
−
{{tp|p=32575019|t=2020. Pirfenidone: A novel hypothetical treatment for COVID-19.|pdf=|usr=010}}
 
−
{{tp|p=32558640|t=2020. Cibler la protease majeure du SARS-CoV-2 pour fabriquer un medicament efficace contre ce coronavirus.|pdf=|usr=010}}
 
  
−
{{tp|p=32574789|t=2020. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).|pdf=|usr=010}}
 
−
{{tp|p=32570850|t=2020. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives.|pdf=|usr=010}}
 
−
{{tp|p=32546125|t=2020. Erythropoietin as candidate for supportive treatment of severe COVID-19.|pdf=|usr=010}}
 
−
{{tp|p=32560203|t=2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.|pdf=|usr=010}}
 
  
−
{{tp|p=32557405|t=2020. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences.|pdf=|usr=010}}
 
−
{{tp|p=32576980|t=2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.|pdf=|usr=010}}
 
  
  
−
{{tp|p=32587103|t=2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?|pdf=|usr=010}}
 
−
{{tp|p=32590117|t=2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.|pdf=|usr=010}}
 
  
−
{{tp|p=32564413|t=2020. Is 0.5% Hydrogen Peroxide Effective against SARS-CoV-2?|pdf=|usr=010}}
 
−
{{tp|p=32587806|t=2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.|pdf=|usr=010}}
 
  
 +
{{tp|p=32547694|t=2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.|pdf=|usr=011}}
  
−
{{tp|p=32565309|t=2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.|pdf=|usr=010}}
 
−
{{tp|p=32592716|t=2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?|pdf=|usr=010}}
 
−
{{tp|p=32562826|t=2020. Therapeutic potential of resveratrol against emerging respiratory viral infections.|pdf=|usr=010}}
 
−
{{tp|p=32542785|t=2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.|pdf=|usr=010}}
 
−
{{tp|p=32592911|t=2020. Does photodynamic therapy have potential in the treatment of COVID 19 patients?|pdf=|usr=010}}
 
−
{{tp|p=32585401|t=2020. Optical theranostics and treatment dosimetry for COVID-19 lung complications: towards increasing the survival rate of vulnerable populations.|pdf=|usr=010}}
 
−
{{tp|p=32585400|t=2020. Ultraviolet-based biophotonic technologies for control and prevention of COVID-19, SARS and related disorders.|pdf=|usr=010}}
 
  
  
  
 +
{{tp|p=32566569|t=2020. Appealing for efficient, well organized clinical trials on COVID-19.|pdf=|usr=011}}
  
−
{{tp|p=32552811|t=2020. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR alpha7 receptor: role of nAChR alpha7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation.|pdf=|usr=010}}
 
  
−
{{tp|p=32557955|t=2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.|pdf=|usr=010}}
 
−
{{tp|p=32571730|t=2020. Anakinra, una alternativa potencial en el tratamiento de la infeccion respiratoria grave por SARS-CoV-2 refractaria a tocilizumab.|pdf=|usr=010}}
 
−
{{ttp|p=32579014|t=2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.|pdf=|usr=010}}
 
−
{{ttp|p=32579012|t=2020. COVID-19. Immunothrombosis and the gastrointestinal tract.|pdf=|usr=010}}
 
  
  
−
{{tp|p=32593196|t=2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.|pdf=|usr=010}}
 
  
  
  
−
{{tp|p=32586154|t=2020. Montelukast's ability to fight COVID-19 infection.|pdf=|usr=010}}
 
−
{{tp|p=32583729|t=2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.|pdf=|usr=010}}
 
−
{{tp|p=32579065|t=2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.|pdf=|usr=010}}
 
  
−
{{tp|p=32579061|t=2020. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro).|pdf=|usr=010}}
 
  
−
{{tp|p=32573355|t=2020. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study.|pdf=|usr=010}}
 
  
−
{{tp|p=32571168|t=2020. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.|pdf=|usr=010}}
 
  
−
{{tp|p=32568618|t=2020. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.|pdf=|usr=010}}
 
−
{{tp|p=32568613|t=2020. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study.|pdf=|usr=010}}
 
−
{{tp|p=32568013|t=2020. Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2.|pdf=|usr=010}}
 
−
{{tp|p=32568012|t=2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.|pdf=|usr=010}}
 
−
{{tp|p=32567995|t=2020. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.|pdf=|usr=010}}
 
−
{{tp|p=32567989|t=2020. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2.|pdf=|usr=010}}
 
−
{{tp|p=32567979|t=2020. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.|pdf=|usr=010}}
 
−
{{tp|p=32567501|t=2020. Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics.|pdf=|usr=010}}
 
  
 +
{{tp|p=32593613|t=2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.|pdf=|usr=011}}
  
  
−
{{tp|p=32559419|t=2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.|pdf=|usr=010}}
 
  
−
{{tp|p=32574572|t=2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.|pdf=|usr=010}}
 
−
{{tp|p=32579258|t=2020. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.|pdf=|usr=010}}
 
−
{{tp|p=32578354|t=2020. Obesity and COVID-19: The mTOR pathway as a possible culprit.|pdf=|usr=010}}
 
  
−
{{tp|p=32588453|t=2020. Covid-19 and Thymoquinone: Connecting the Dots.|pdf=|usr=010}}
 
−
{{ttp|p=32552307|t=2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.|pdf=|usr=010}}
 
  
−
{{tp|p=32569363|t=2020. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study.|pdf=|usr=010}}
 
  
−
{{tp|p=32568376|t=2020. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.|pdf=|usr=010}}
 
−
{{tp|p=32556278|t=2020. Real-life experience of tocilizumab use in COVID-19 patients.|pdf=|usr=010}}
 
−
{{tp|p=32543892|t=2020. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.|pdf=|usr=010}}
 
  
 +
{{tp|p=32532425|t=2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?|pdf=|usr=011}}
 +
{{tp|p=32557557|t=2020. Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19?|pdf=|usr=011}}
  
−
{{tp|p=32573990|t=2020. Heart Transplant Recipient Patient with COVID-19 Treated with Tocilizumab.|pdf=|usr=010}}
 
−
{{tp|p=32584762|t=2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].|pdf=|usr=010}}
 
  
  
  
  
−
{{tp|p=32547694|t=2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.|pdf=|usr=011}}
 
−
{{tp|p=32547693|t=2020. A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin.|pdf=|usr=011}}
 
  
  
−
{{tp|p=32593520|t=2020. Tocilizumab en nino con leucemia linfoblastica aguda y sindrome de liberacion de citoquinas asociado a COVID-19.|pdf=|usr=011}}
 
−
{{tp|p=32566569|t=2020. Appealing for efficient, well organized clinical trials on COVID-19.|pdf=|usr=011}}
 
  
  
  
  
−
{{tp|p=32545171|t=2020. Antimicrobial Photodynamic Therapy in the Control of COVID-19.|pdf=|usr=011}}
+
{{tp|p=32383125|t=2020. Prophylaxie post-exposition ou traitement preventif pour le syndrome respiratoire aigu severe du coronavirus 2 (SARS-CoV-2) : protocole d'etude pour une etude randomisee controlee pragmatique.|pdf=|usr=011}}
−
{{tp|p=32545518|t=2020. Nrf2 Activator PB125((R)) as a Potential Therapeutic Agent against COVID-19.|pdf=|usr=011}}
+
  
−
{{tp|p=32536457|t=2020. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?|pdf=|usr=011}}
+
{{tp|p=32385712|t=2020. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?|pdf=|usr=011}}
−
{{tp|p=32546446|t=2020. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?|pdf=|usr=011}}
+
  
−
{{tp|p=32594322|t=2020. Antiviral activity of berberine.|pdf=|usr=011}}
 
  
−
{{tp|p=32593613|t=2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.|pdf=|usr=011}}
 
  
  
  
  
−
{{tp|p=32599963|t=2020. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.|pdf=|usr=011}}
 
−
{{tp|p=32536632|t=2020. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.|pdf=|usr=011}}
 
−
{{tp|p=32459144|t=2020. Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking.|pdf=|usr=011}}
 
−
{{tp|p=32532425|t=2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?|pdf=|usr=011}}
 
−
{{tp|p=32557557|t=2020. Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19?|pdf=|usr=011}}
 
  
−
{{tp|p=32571773|t=2020. Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.|pdf=|usr=011}}
 
  
  
Zeile 506: Zeile 395:
  
  
−
{{tp|p=32603679|t=2020. Calcineurin inhibitors revisited: A new paradigm for COVID-19?|pdf=|usr=011}}
 
  
  
−
{{tp|p=32383125|t=2020. Prophylaxie post-exposition ou traitement preventif pour le syndrome respiratoire aigu severe du coronavirus 2 (SARS-CoV-2) : protocole d'etude pour une etude randomisee controlee pragmatique.|pdf=|usr=011}}
 
  
−
{{tp|p=32385712|t=2020. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?|pdf=|usr=011}}
 
−
{{tp|p=32389579|t=2020. Irradiation pulmonaire a faible dose pour l'orage de cytokines du COVID-19 : pourquoi pas ?|pdf=|usr=011}}
 
−
{{tp|p=32411313|t=2020. FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.|pdf=|usr=011}}
 
  
  
  
 +
{{tp|p=32610153|t=2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.|pdf=|usr=011}}
  
−
{{tp|p=32409956|t=2020. Possible application of H2S-producing compounds in therapy of coronavirus (COVID-19) infection and pneumonia.|pdf=|usr=011}}
 
  
−
{{tp|p=32599278|t=2020. Imatinib for COVID-19: A case report.|pdf=|usr=011}}
 
−
{{tp|p=32607779|t=2020. Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?|pdf=|usr=011}}
 
−
{{tp|p=32594204|t=2020. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?|pdf=|usr=011}}
 
  
  
  
−
{{tp|p=32598985|t=2020. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.|pdf=|usr=011}}
 
  
  
−
{{tp|p=32606823|t=2020. Potential Role of Nrf2 Activators with Dual Antiviral and Anti-Inflammatory Properties in the Management of Viral Pneumonia.|pdf=|usr=011}}
 
  
−
{{tp|p=32610153|t=2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.|pdf=|usr=011}}
+
{{tp|p=32584416|t=2020. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.|pdf=|usr=011}}
 +
 
 +
{{tp|p=32536693|t=2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?|pdf=|usr=011}}
 +
 
 +
 
  
  
Zeile 537: Zeile 420:
  
  
−
{{tp|p=32593183|t=2020. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.|pdf=|usr=011}}
 
  
−
{{ttp|p=32584421|t=2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.|pdf=|usr=011}}
 
−
{{tp|p=32584416|t=2020. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.|pdf=|usr=011}}
 
  
−
{{tp|p=32536693|t=2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?|pdf=|usr=011}}
 
  
−
{{tp|p=32553536|t=2020. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes.|pdf=|usr=011}}
 
  
  
−
{{tp|p=32573419|t=2020. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.|pdf=|usr=011}}
 
−
{{tp|p=32597466|t=2020. Use of Baricitinib in Patients with Moderate and Severe COVID-19.|pdf=|usr=011}}
 
  
−
{{tp|p=32594120|t=2020. Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors.|pdf=|usr=011}}
 
−
{{tp|p=32575124|t=2020. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.|pdf=|usr=011}}
 
  
  
  
−
{{tp|p=32536564|t=2020. IL-15 immunotherapy is a viable strategy for COVID-19.|pdf=|usr=011}}
 
−
{{tp|p=32540737|t=2020. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?|pdf=|usr=011}}
 
  
−
{{tp|p=32603531|t=2020. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.|pdf=|usr=011}}
 
  
  
−
{{tp|p=32518817|t=2020. Synthesis, Spectroscopic Characterizations of Novel Norcantharimides, Their ADME Properties and Docking Studies Against COVID-19 M(pr) degrees .|pdf=|usr=011}}
 
 
{{tp|p=32572383|t=2020. Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation.|pdf=|usr=011}}
 
{{tp|p=32572383|t=2020. Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation.|pdf=|usr=011}}
  
 
{{tp|p=32548601|t=2020. Ventilation in the Dental Clinic: An Effective Measure to Control Droplets and Aerosols during the Coronavirus Pandemic and Beyond.|pdf=|usr=011}}
 
{{tp|p=32548601|t=2020. Ventilation in the Dental Clinic: An Effective Measure to Control Droplets and Aerosols during the Coronavirus Pandemic and Beyond.|pdf=|usr=011}}
 
{{tp|p=32548600|t=2020. Preventive and Control Measures for the Coronavirus Pandemic in Clinical Dentistry.|pdf=|usr=011}}
 
{{tp|p=32548600|t=2020. Preventive and Control Measures for the Coronavirus Pandemic in Clinical Dentistry.|pdf=|usr=011}}
−
{{tp|p=32242749|t=2020. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?|pdf=|usr=011}}
 
  
−
{{tp|p=32533455|t=2020. Azithromycin for COVID-19: More Than Just an Antimicrobial?|pdf=|usr=011}}
+
 
 +
 
  
  
Zeile 574: Zeile 444:
  
 
{{tp|p=32417594|t=2020. Supplements for COVID-19: A modifiable environmental risk.|pdf=|usr=011}}
 
{{tp|p=32417594|t=2020. Supplements for COVID-19: A modifiable environmental risk.|pdf=|usr=011}}
−
{{tp|p=32405269|t=2020. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.|pdf=|usr=011}}
+
 
−
{{tp|p=32409832|t=2020. SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.|pdf=|usr=011}}
+
 
  
 
{{tp|p=32407539|t=2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?|pdf=|usr=011}}
 
{{tp|p=32407539|t=2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?|pdf=|usr=011}}
Zeile 587: Zeile 457:
  
 
{{tp|p=32392494|t=2020. Sample sizes in COVID-19-related research.|pdf=|usr=011}}
 
{{tp|p=32392494|t=2020. Sample sizes in COVID-19-related research.|pdf=|usr=011}}
−
{{tp|p=32485652|t=2020. Interaction of the prototypical alpha-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.|pdf=|usr=011}}
 
  
  
−
{{tp|p=32384906|t=2020. Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial.|pdf=|usr=011}}
+
 
 +
 
  
  
Zeile 596: Zeile 466:
 
{{tp|p=32513225|t=2020. Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?|pdf=|usr=011}}
 
{{tp|p=32513225|t=2020. Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?|pdf=|usr=011}}
 
{{tp|p=32487260|t=2020. Precision medicine for COVID-19: a call for better clinical trials.|pdf=|usr=011}}
 
{{tp|p=32487260|t=2020. Precision medicine for COVID-19: a call for better clinical trials.|pdf=|usr=011}}
−
{{tp|p=32487139|t=2020. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?|pdf=|usr=011}}
 
  
  
  
  
−
{{tp|p=32494546|t=2020. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.|pdf=|usr=011}}
+
 
 +
 
  
 
{{tp|p=32550078|t=2020. Heated Air Delivery by Micro-Sauna: An Experimental Treatment Prototype Concept for Coronavirus Disease 2019.|pdf=|usr=011}}
 
{{tp|p=32550078|t=2020. Heated Air Delivery by Micro-Sauna: An Experimental Treatment Prototype Concept for Coronavirus Disease 2019.|pdf=|usr=011}}
  
−
{{tp|p=32563554|t=2020. Should we unstress SARS-CoV-2 infected cells?|pdf=|usr=011}}
+
{{ttp|p=32563554|t=2020. Should we unstress SARS-CoV-2 infected cells?|pdf=|usr=011}}
  
  
  
−
{{tp|p=32593491|t=2020. Molecular pharmacology of ciclesonide against SARS-CoV-2.|pdf=|usr=011}}
 
  
  
−
{{tp|p=32605278|t=2020. Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19.|pdf=|usr=011}}
 
  
  
 
{{tp|p=32605149|t=2020. Bioactive Indolyl Diketopiperazines from the Marine Derived Endophytic Aspergillus versicolor DY180635.|pdf=|usr=011}}
 
{{tp|p=32605149|t=2020. Bioactive Indolyl Diketopiperazines from the Marine Derived Endophytic Aspergillus versicolor DY180635.|pdf=|usr=011}}
−
{{tp|p=32593831|t=2020. Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19.|pdf=|usr=011}}
 
  
−
{{tp|p=32593740|t=2020. Irisin modulates genes associated with severe coronavirus disease (COVID-19) outcome in human subcutaneous adipocytes.|pdf=|usr=011}}
 
−
{{tp|p=32602074|t=2020. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.|pdf=|usr=011}}
 
  
  
−
{{tp|p=32597315|t=2020. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.|pdf=|usr=011}}
+
 
−
{{tp|p=32608329|t=2020. In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme.|pdf=|usr=011}}
+
 
 +
 
 +
 
 +
 
 
{{tp|p=32520770|t=2020. Overview of Coronavirus Disease 2019 (COVID-19): Treatment Updates and Advances.|pdf=|usr=011}}
 
{{tp|p=32520770|t=2020. Overview of Coronavirus Disease 2019 (COVID-19): Treatment Updates and Advances.|pdf=|usr=011}}
−
{{tp|p=32530870|t=2020. Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections.|pdf=|usr=011}}
 
−
{{tp|p=32570043|t=2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.|pdf=|usr=011}}
 
  
  
  
  
−
{{tp|p=32579254|t=2020. SARS-CoV-2 and SARS-CoV: Virtual Screening of Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12).|pdf=|usr=011}}
+
 
−
{{tp|p=32568411|t=2020. Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm.|pdf=|usr=011}}
+
 
 +
 
 +
 
 
{{tp|p=32574379|t=2020. A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.org/10.1111/jnc.15021.|pdf=|usr=011}}
 
{{tp|p=32574379|t=2020. A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.org/10.1111/jnc.15021.|pdf=|usr=011}}
−
{{ttp|p=32597503|t=2020. Melatonin Restores Neutrophil Functions and Prevents Apoptosis amid Dysfunctional Glutathione Redox System.|pdf=|usr=011}}
+
 
−
{{tp|p=32543164|t=2020. The comparison of the effectiveness of lincocin(R) and azitro(R) in the treatment of covid-19-associated pneumonia: A prospective study.|pdf=|usr=011}}
+
 
−
{{tp|p=32608097|t=2020. Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses.|pdf=|usr=011}}
+
 
  
  
Zeile 643: Zeile 511:
  
  
−
{{tp|p=32447665|t=2020. Mit IL-6-Inhibitor gegen COVID-19 : Corona-Pandemie.|pdf=|usr=011}}
 
−
{{tp|p=32342366|t=2020. Autophagie - ein Ansatzpunkt fur ein Medikament gegen COVID-19? : Kampf gegen das Coronavirus.|pdf=|usr=011}}
 
  
  
  
−
{{tp|p=32524646|t=2020. Lithium as a candidate treatment for COVID-19: Promises and pitfalls.|pdf=|usr=011}}
 
  
−
{{tp|p=32425222|t=2020. Repurposing chlorpromazine to treat COVID-19: The reCoVery study.|pdf=|usr=011}}
+
 
 +
 
 +
 
 +
 
  
  
Zeile 656: Zeile 524:
  
  
−
{{tp|p=32563813|t=2020. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase.|pdf=|usr=011}}
+
 
−
{{tp|p=32525005|t=2020. Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target.|pdf=|usr=011}}
+
 
  
  
 
{{tp|p=32399192|t=2020. Recent advances in influenza vaccines.|pdf=|usr=011}}
 
{{tp|p=32399192|t=2020. Recent advances in influenza vaccines.|pdf=|usr=011}}
  
−
{{tp|p=32596244|t=2020. The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and Its Potential Use in the Associated Severe Pneumonia.|pdf=|usr=011}}
 
−
{{tp|p=32595653|t=2020. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.|pdf=|usr=011}}
 
  
−
{{tp|p=32574274|t=2020. Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?|pdf=|usr=011}}
 
−
{{tp|p=32574273|t=2020. Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?|pdf=|usr=011}}
 
  
  
Zeile 673: Zeile 537:
  
  
−
{{tp|p=32582742|t=2020. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection.|pdf=|usr=011}}
 
  
−
{{tp|p=32574339|t=2020. Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia.|pdf=|usr=011}}
 
−
{{tp|p=32574332|t=2020. Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.|pdf=|usr=011}}
 
−
{{tp|p=32574331|t=2020. May Polyphenols Have a Role Against Coronavirus Infection? An Overview of in vitro Evidence.|pdf=|usr=011}}
 
−
{{tp|p=32574327|t=2020. Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19.|pdf=|usr=011}}
 
−
{{tp|p=32574320|t=2020. Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.|pdf=|usr=011}}
 
  
−
{{tp|p=32582138|t=2020. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection.|pdf=|usr=011}}
 
−
{{tp|p=32582137|t=2020. Biosurfactants: A Covid-19 Perspective.|pdf=|usr=011}}
 
−
{{tp|p=32582134|t=2020. Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections.|pdf=|usr=011}}
 
  
−
{{tp|p=32581810|t=2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.|pdf=|usr=011}}
 
−
{{tp|p=32581809|t=2020. Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.|pdf=|usr=011}}
 
−
{{tp|p=32574238|t=2020. An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?|pdf=|usr=011}}
 
  
  
  
  
−
{{tp|p=32574290|t=2020. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic.|pdf=|usr=011}}
 
  
−
{{tp|p=32547908|t=2020. Ultraviolet irradiation doses for coronavirus inactivation - review and analysis of coronavirus photoinactivation studies.|pdf=|usr=011}}
+
 
−
{{tp|p=32566483|t=2020. Doxycycline as a potential partner of COVID-19 therapies.|pdf=|usr=011}}
+
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
  
  
Zeile 702: Zeile 570:
  
  
−
{{tp|p=32534505|t=2020. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.|pdf=|usr=011}}
+
 
−
{{tp|p=32558435|t=2020. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.|pdf=|usr=011}}
+
 
−
{{tp|p=32565398|t=2020. Effects of Micronutrients or Conditional Amino Acids on COVID-19-Related Outcomes: An Evidence Analysis Center Scoping Review.|pdf=|usr=011}}
+
 
  
 
{{tp|p=32552595|t=2020. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation.|pdf=|usr=011}}
 
{{tp|p=32552595|t=2020. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation.|pdf=|usr=011}}
−
{{tp|p=32552534|t=2020. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.|pdf=|usr=011}}
+
 
 
{{tp|p=32552462|t=2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.|pdf=|usr=011}}
 
{{tp|p=32552462|t=2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.|pdf=|usr=011}}
−
{{tp|p=32552361|t=2020. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro).|pdf=|usr=011}}
+
 
−
{{tp|p=32544024|t=2020. An in silico approach for identification of novel inhibitors as potential therapeutics targeting COVID-19 main protease.|pdf=|usr=011}}
+
 
 
{{tp|p=32543978|t=2020. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials.|pdf=|usr=011}}
 
{{tp|p=32543978|t=2020. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials.|pdf=|usr=011}}
−
{{tp|p=32538276|t=2020. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies.|pdf=|usr=011}}
 
  
  
  
−
{{ttp|p=32600125|t=2020. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection.|pdf=|usr=011}}
+
 
 +
 
  
  
Zeile 724: Zeile 592:
  
  
−
{{tp|p=32597513|t=2020. New intrigant possibility for prevention of coronavirus pneumonitis: natural purified polyphenols.|pdf=|usr=011}}
 
−
{{tp|p=32541085|t=2020. Citokinellenes terapia az uj tipusu koronavirus okozta megbetegedes (COVID-19) kezeleseben - tocilizumab elsokent valo alkalmazasa egy hazai infektologiai osztalyon.|pdf=|usr=011}}
 
  
−
{{tp|p=32579049|t=2020. Photobiomodulation: Shining Light on COVID-19.|pdf=|usr=011}}
 
−
{{tp|p=32579493|t=2020. Response to: Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?|pdf=|usr=011}}
 
−
{{tp|p=32579491|t=2020. Author's Response to Ferreira: Can Transdermal Photobiomodulation Help Us at the Time of COVID-19? An Update.|pdf=|usr=011}}
 
  
  
Zeile 735: Zeile 598:
  
  
−
{{tp|p=32604223|t=2020. Therapeutic Potential of B-1a Cells in COVID-19.|pdf=|usr=011}}
+
 
 +
 
 +
 
 
{{tp|p=32553502|t=2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.|pdf=|usr=011}}
 
{{tp|p=32553502|t=2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.|pdf=|usr=011}}
  
−
{{tp|p=32574447|t=2020. HBO2 for COVID-19: Clinical trials at clinicaltrials.gov.|pdf=|usr=011}}
 
−
{{tp|p=32574446|t=2020. UHMS Position Statement: Hyperbaric Oxygen (HBO2) for COVID-19 Patients.|pdf=|usr=011}}
 
−
{{tp|p=32574433|t=2020. Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports.|pdf=|usr=011}}
 
−
{{tp|p=32574432|t=2020. Hyperbaric oxygen as a treatment for COVID-19 infection?|pdf=|usr=011}}
 
−
{{tp|p=32567972|t=2020. Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway.|pdf=|usr=011}}
 
  
  
−
{{tp|p=32530282|t=2020. Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease.|pdf=|usr=011}}
+
 
−
{{tp|p=32539372|t=2020. Fragment Molecular Orbital Based Interaction Analyses on COVID-19 Main Protease - Inhibitor N3 Complex (PDB ID: 6LU7).|pdf=|usr=011}}
+
 
−
{{tp|p=32551639|t=2020. Discovery of New Hydroxyethylamine Analogs against 3CL(pro) Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies.|pdf=|usr=011}}
+
  
  
 
{{tp|p=32551855|t=2020. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.|pdf=|usr=011}}
 
{{tp|p=32551855|t=2020. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.|pdf=|usr=011}}
  
−
{{tp|p=32592703|t=2020. Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia.|pdf=|usr=011}}
 
−
{{tp|p=32579985|t=2020. Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients: Etoposide for severe COVID-19 patients.|pdf=|usr=011}}
 
  
−
{{tp|p=32515499|t=2020. Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6.|pdf=|usr=011}}
 
  
  
  
−
{{tp|p=32519764|t=2020. Could melatonin be used in COVID-19 patients with laryngopharyngeal reflux disease?|pdf=|usr=011}}
+
 
 +
 
 +
 
 +
 
  
 
{{tp|p=32454982|t=2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.|pdf=|usr=011}}
 
{{tp|p=32454982|t=2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.|pdf=|usr=011}}
−
{{tp|p=32542782|t=2020. SARS-CoV-2 Viral Inactivation Using Low Dose Povidone-Iodine Oral Rinse-Immediate Application for the Prosthodontic Practice.|pdf=|usr=011}}
+
 
 
{{tp|p=32582350|t=2020. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property.|pdf=|usr=011}}
 
{{tp|p=32582350|t=2020. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property.|pdf=|usr=011}}
 
{{tp|p=32600410|t=2020. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.|pdf=|usr=011}}
 
{{tp|p=32600410|t=2020. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.|pdf=|usr=011}}
Zeile 769: Zeile 628:
  
 
{{tp|p=32539990|t=2020. A minimal common outcome measure set for COVID-19 clinical research.|pdf=|usr=011}}
 
{{tp|p=32539990|t=2020. A minimal common outcome measure set for COVID-19 clinical research.|pdf=|usr=011}}
−
{{tp|p=32402512|t=2020. A Case of Coronavirus Disease 2019 Treated With Ciclesonide.|pdf=|usr=011}}
+
 
−
{{tp|p=32577056|t=2020. The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role?|pdf=|usr=011}}
+
 
 
{{tp|p=32537610|t=2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.|pdf=|usr=011}}
 
{{tp|p=32537610|t=2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.|pdf=|usr=011}}
  
Zeile 777: Zeile 636:
  
 
{{tp|p=32554324|t=2020. Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects.|pdf=|usr=011}}
 
{{tp|p=32554324|t=2020. Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects.|pdf=|usr=011}}
−
{{tp|p=32540603|t=2020. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.|pdf=|usr=011}}
+
 
 
{{tp|p=32563970|t=2020. Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.|pdf=|usr=011}}
 
{{tp|p=32563970|t=2020. Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.|pdf=|usr=011}}
  
−
{{tp|p=32554149|t=2020. Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy.|pdf=|usr=011}}
 
  
  
  
  
−
{{tp|p=32405836|t=2020. Wie ernahre ich mich am besten in Zeiten der Corona-Pandemie? : COVID-19 und Ernahrungsmedizin.|pdf=|usr=011}}
+
 
 +
 
  
 
{{tp|p=32545268|t=2020. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.|pdf=|usr=011}}
 
{{tp|p=32545268|t=2020. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.|pdf=|usr=011}}
Zeile 791: Zeile 650:
  
  
−
{{tp|p=32550240|t=2020. Azithromycin Should Not Be Used to Treat COVID-19.|pdf=|usr=011}}
+
 
−
{{tp|p=32582329|t=2020. How Nutrition can help to fight against COVID-19 Pandemic.|pdf=|usr=011}}
+
 
−
{{tp|p=32582320|t=2020. Beyond transmission: Dire need for integration of nutrition interventions in COVID-19 pandemic-response strategies in Developing Countries like Pakistan.|pdf=|usr=011}}
+
 
−
{{tp|p=32582873|t=2020. Evaluation of Ultraviolet-C Light for Rapid Decontamination of Airport Security Bins in the Era of SARS-CoV-2.|pdf=|usr=011}}
+
 
  
  
Zeile 803: Zeile 662:
  
  
−
{{tp|p=32583654|t=2020. Baricitinib en el tratamiento de infeccion por SARS-CoV-2.|pdf=|usr=011}}
+
 
  
 
{{tp|p=32548259|t=2020. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.|pdf=|usr=011}}
 
{{tp|p=32548259|t=2020. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.|pdf=|usr=011}}
 
{{tp|p=32601278|t=2020. Numerical evaluation of spray position for improved nasal drug delivery.|pdf=|usr=011}}
 
{{tp|p=32601278|t=2020. Numerical evaluation of spray position for improved nasal drug delivery.|pdf=|usr=011}}
−
{{tp|p=32581288|t=2020. Far-UVC light (222 nm) efficiently and safely inactivates airborne human coronaviruses.|pdf=|usr=011}}
+
 
 
{{tp|p=32576928|t=2020. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.|pdf=|usr=011}}
 
{{tp|p=32576928|t=2020. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.|pdf=|usr=011}}
−
{{tp|p=32577236|t=2020. Preventing SARS-CoV-2 infection by blocking a tissue serine protease.|pdf=|usr=011}}
+
 
−
{{tp|p=32539647|t=2020. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.|pdf=|usr=011}}
+
 
 
{{tp|p=32583289|t=2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.|pdf=|usr=011}}
 
{{tp|p=32583289|t=2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.|pdf=|usr=011}}
 
{{tp|p=32557317|t=2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32557317|t=2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.|pdf=|usr=011}}
Zeile 816: Zeile 675:
 
{{tp|p=32563584|t=2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.|pdf=|usr=011}}
 
{{tp|p=32563584|t=2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.|pdf=|usr=011}}
  
−
{{tp|p=32580895|t=2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.|pdf=|usr=011}}
 
  
−
{{tp|p=32551456|t=2020. Use of Spironolactone in SARS-CoV-2 ARDS Patients.|pdf=|usr=011}}
+
 
 +
 
  
 
{{tp|p=32595360|t=2020. Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties.|pdf=|usr=011}}
 
{{tp|p=32595360|t=2020. Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties.|pdf=|usr=011}}
Zeile 824: Zeile 683:
  
  
−
{{tp|p=32595355|t=2020. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target.|pdf=|usr=011}}
 
  
−
{{tp|p=32575350|t=2020. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.|pdf=|usr=011}}
 
  
  
  
  
−
{{tp|p=32565126|t=2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.|pdf=|usr=011}}
 
  
−
{{tp|p=32573126|t=2020. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?|pdf=|usr=011}}
+
 
 +
{{tp|p=32565126|t=2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.|pdf=|usr=011}}

Version vom 8. Juli 2020, 10:37 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.










32445955 2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"











32426002 2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.










32376108 2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.





32426090 2020. COVID-19, asthma, and biologic therapies: What we need to know.


32514854 2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.














32558354 2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.




32562159 2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.






32592145 2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.




32562594 2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.



32578073 2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.
32577840 2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.



32588335 2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.









32552021 2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.



32551560 2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.



32561608 2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.
32574109 2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.







32567239 2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.




















32587103 2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?





32565309 2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.







32557955 2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.

32579012 2020. COVID-19. Immunothrombosis and the gastrointestinal tract.



32593196 2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.




32583729 2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.







32568012 2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.
















32547694 2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.




32566569 2020. Appealing for efficient, well organized clinical trials on COVID-19.








32593613 2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.





32532425 2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?
32557557 2020. Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19?







32383125 2020. Prophylaxie post-exposition ou traitement preventif pour le syndrome respiratoire aigu severe du coronavirus 2 (SARS-CoV-2) : protocole d'etude pour une etude randomisee controlee pragmatique.


32385712 2020. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?











32610153 2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.






32584416 2020. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.


32536693 2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?











32572383 2020. Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation.


32548601 2020. Ventilation in the Dental Clinic: An Effective Measure to Control Droplets and Aerosols during the Coronavirus Pandemic and Beyond.
32548600 2020. Preventive and Control Measures for the Coronavirus Pandemic in Clinical Dentistry.




32544611 2020. Development of child immunity in the context of COVID-19 pandemic.


32417594 2020. Supplements for COVID-19: A modifiable environmental risk.



32407539 2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?


32311763 2020. Off-Label Therapies for COVID-19-Are We All In This Together?



32388748 2020. Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?


32575032 2020. Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed.


32392494 2020. Sample sizes in COVID-19-related research.





32513242 2020. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.
32513225 2020. Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?
32487260 2020. Precision medicine for COVID-19: a call for better clinical trials.





32550078 2020. Heated Air Delivery by Micro-Sauna: An Experimental Treatment Prototype Concept for Coronavirus Disease 2019.

32563554 2020. Should we unstress SARS-CoV-2 infected cells?





32605149 2020. Bioactive Indolyl Diketopiperazines from the Marine Derived Endophytic Aspergillus versicolor DY180635.






32520770 2020. Overview of Coronavirus Disease 2019 (COVID-19): Treatment Updates and Advances.






32574379 2020. A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.org/10.1111/jnc.15021.




32541129 2020. Intermittent high dosage oxygen treats COVID-19 infection: the Chinese studies.
32541128 2020. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure.








32544799 2020. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.





32399192 2020. Recent advances in influenza vaccines.




















32540428 2020. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.
32537482 2020. Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach.





32552595 2020. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation.


32552462 2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.



32543978 2020. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials.






32605306 2020. Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.








32553502 2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.





32551855 2020. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.







32454982 2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.


32582350 2020. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property.
32600410 2020. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.



32539990 2020. A minimal common outcome measure set for COVID-19 clinical research.



32537610 2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.



32540604 2020. Iodine, a preventive and curative agent in the COVID-19 pandemic?


32554324 2020. Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects.


32563970 2020. Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.






32545268 2020. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.







32540682 2020. Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis.




32548259 2020. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.
32601278 2020. Numerical evaluation of spray position for improved nasal drug delivery.


32576928 2020. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.



32583289 2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.
32557317 2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.


32563584 2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.




32595360 2020. Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties.
32595359 2020. Potentials of plant-based substance to inhabit and probable cure for the COVID-19.






32565126 2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.

Von „http://coviki.org/cov/index.php?title=Candidate_Compounds_Covid19&oldid=3483“
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis